Healthcare stocks were mixed in afternoon trading. The
S&P/TSX Healthcare index was up 0.2%.
Valeant Pharmaceuticals (VRX.TO): +0.3%
QLT Inc. (QLT.TO): +0.5%
Tekmira Pharmaceuticals (TKM.TO): -2.7%
Catamaran (CCT.TO): -0.1%
Oncolytics Biotech (ONC.TO): +2.9%
In corporate news, Valeant Pharmaceuticals Monday filed a
pre-merger notification under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976 with the US Federal Trade Commission
relating to the proposed acquisition of Allergan (
), a multi-speciality health care company.
Meanwhile, QLT Inc. Monday published data from its Phase 1b
proof of concept trial of QLT091001 to treat a condition that can
cause blindness, saying patients using the product saw significant
improvement. QLT091001 is being assessed in subjects with Leber
Congenital Amaurosis (LCA) due to inherited genetic mutations in
retinal pigment epithelium (RPE65) or lecithin:retinol
acyltransferase. In the study, treatment for 7 days with oral
QLT091001 demonstrated a restoration of clinically meaningful
visual function in 11 of the 14 LCA patients, as measured by
improvement in Goldmann Visual Fields (GVF) or visual acuity.